en
Nieuwsbrief
Cases

Dualyx

  • Start-ups & scale-ups
  • Life Sciences & Care
  • Portfolio Life Sciences & Care
  • Life sciences & care
Luc Van Rompaey - Dualyx

With the support of our investors and partners, we can continue our research into innovative therapies.

Luc Van Rompaey, founder and CSO at Dualyx

Innovative drugs for autoimmune diseases

Biotech company Dualyx was founded in 2019 as a spin-off of KU Leuven. It focuses on the discovery and development of innovative ‘biologicals’ (immune modulating drugs) for the treatment of (auto)immune diseases and rare infectious diseases (AID).

Dualyx is currently still in its R&D phase and works closely with the German University of W├╝rzburg, the VIB, UGent, the Ghent biotech company Argenx and the KUL. The first scientific results are very promising.

Partners in ambition at Dualyx

In a first investment round Dualyx raised start-up capital in two phases from investors including V-Bio, Biogeneration Ventures, High-Tech Gr├╝nderfonds, Gemma Frisius, VIB and PMV.

This funding was extended to enable Dualyx to continue its research, expand the team and build its own lab.

Investment team Dualyx

Nathalie Van Bruaene Investment manager nathalie.vanbruaene@pmv.eu
Tine Bekaert Senior Investment Manager tine.bekaert@pmv.eu